JP2013521297A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013521297A5 JP2013521297A5 JP2012556166A JP2012556166A JP2013521297A5 JP 2013521297 A5 JP2013521297 A5 JP 2013521297A5 JP 2012556166 A JP2012556166 A JP 2012556166A JP 2012556166 A JP2012556166 A JP 2012556166A JP 2013521297 A5 JP2013521297 A5 JP 2013521297A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- symptoms
- hormonal
- dextromethorphan
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 22
- 230000003054 hormonal effect Effects 0.000 claims 10
- 208000024891 symptom Diseases 0.000 claims 10
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims 6
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 claims 6
- 229960001985 dextromethorphan Drugs 0.000 claims 6
- 239000012848 Dextrorphan Substances 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- JAQUASYNZVUNQP-PVAVHDDUSA-N dextrorphan Chemical compound C1C2=CC=C(O)C=C2[C@@]23CCN(C)[C@@H]1[C@H]2CCCC3 JAQUASYNZVUNQP-PVAVHDDUSA-N 0.000 claims 4
- 229950006878 dextrorphan Drugs 0.000 claims 4
- 206010029410 night sweats Diseases 0.000 claims 4
- 230000036565 night sweats Effects 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 229960002870 gabapentin Drugs 0.000 claims 3
- 206010016825 Flushing Diseases 0.000 claims 2
- 206010060800 Hot flush Diseases 0.000 claims 2
- 238000013270 controlled release Methods 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 238000013268 sustained release Methods 0.000 claims 2
- 239000012730 sustained-release form Substances 0.000 claims 2
- YKFCISHFRZHKHY-NGQGLHOPSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid;trihydrate Chemical compound O.O.O.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 YKFCISHFRZHKHY-NGQGLHOPSA-N 0.000 claims 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims 1
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 claims 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 claims 1
- 229940083181 centrally acting adntiadrenergic agent methyldopa Drugs 0.000 claims 1
- 229940035811 conjugated estrogen Drugs 0.000 claims 1
- 229960002866 duloxetine Drugs 0.000 claims 1
- 229960002464 fluoxetine Drugs 0.000 claims 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 claims 1
- 229960002073 sertraline Drugs 0.000 claims 1
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 claims 1
- 229960004688 venlafaxine Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30963810P | 2010-03-02 | 2010-03-02 | |
| US61/309,638 | 2010-03-02 | ||
| PCT/US2011/026650 WO2011109367A2 (en) | 2010-03-02 | 2011-03-01 | Methods and compositions for treating or preventing symptoms of hormonal variations |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013521297A JP2013521297A (ja) | 2013-06-10 |
| JP2013521297A5 true JP2013521297A5 (enExample) | 2014-05-15 |
| JP5839362B2 JP5839362B2 (ja) | 2016-01-06 |
Family
ID=44531862
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012556166A Active JP5839362B2 (ja) | 2010-03-02 | 2011-03-01 | ホルモン変動の症状を治療または予防するための方法および組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20110218213A1 (enExample) |
| EP (1) | EP2542241B1 (enExample) |
| JP (1) | JP5839362B2 (enExample) |
| CN (1) | CN102858343B (enExample) |
| AU (3) | AU2011223807B2 (enExample) |
| BR (1) | BR112012022052B1 (enExample) |
| CA (1) | CA2828041C (enExample) |
| EA (1) | EA027350B1 (enExample) |
| ES (1) | ES2574210T3 (enExample) |
| IL (2) | IL221706A (enExample) |
| PL (1) | PL2542241T3 (enExample) |
| WO (1) | WO2011109367A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9616123B1 (en) * | 2012-03-05 | 2017-04-11 | Robert L. Knobler | Method and compound for treatment of menopausal symptoms |
| CN107249615B (zh) * | 2015-04-07 | 2021-02-05 | 株式会社明治 | 潮热抑制剂 |
| US11491120B2 (en) | 2017-11-09 | 2022-11-08 | The Trustees Of Columbia University In The City Of New York | Pharmacological prophylactics against stress-induced affective disorders in females |
| US11622948B2 (en) | 2017-11-09 | 2023-04-11 | The Trustees Of Columbia University In The City Of New York | Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders |
| WO2020219270A1 (en) * | 2019-04-22 | 2020-10-29 | Knobler Robert L | Non-hormonal treatment of hot flashes |
| WO2021108801A2 (en) * | 2019-11-15 | 2021-06-03 | Consegna Pharma, Inc. | Long acting nmda antagonists |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5321012A (en) * | 1993-01-28 | 1994-06-14 | Virginia Commonwealth University Medical College | Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance |
| CA2115792C (en) * | 1993-03-05 | 2005-11-01 | David J. Mayer | Method for the treatment of pain |
| EP2275089A1 (en) * | 1993-11-19 | 2011-01-19 | Alkermes Controlled Therapeutics, Inc. | Preparation of biodegradable microparticles containing a biologically active agent |
| AUPN605795A0 (en) * | 1995-10-19 | 1995-11-09 | F.H. Faulding & Co. Limited | Analgesic pharmaceutical composition |
| DE60034344T2 (de) * | 1999-07-22 | 2008-01-10 | University Of Rochester | Methode zur behandlung der symptome hormoneller veränderungen, einschliesslich hitzewallungen |
| US20040002482A1 (en) * | 2000-08-30 | 2004-01-01 | Dudley Robert E. | Androgen pharmaceutical composition and method for treating depression |
| US6569471B2 (en) * | 2000-09-01 | 2003-05-27 | Natumin Pharma Ab | Method for the treatment of symptoms related to normal hormonal variations in women |
| US20050129783A1 (en) * | 2001-04-19 | 2005-06-16 | Mccleary Edward L. | Composition and method for treatment of neurophysiological conditions and maintenance of neurophysiological health |
| US20040259850A1 (en) * | 2001-10-31 | 2004-12-23 | Alves Stephen E. | Method for treating or preventing symptoms of hormonal variation including hot flashes |
| UA81423C2 (en) * | 2002-08-15 | 2008-01-10 | PRODUCT CONTAINING SRI AND AGONIST OF THE 5HT2a RECEPTOR FOR TREATMENT OF THERMOREGULATORY DYSFUNCTION | |
| HUP0303313A2 (hu) * | 2003-10-09 | 2005-07-28 | Richter Gedeon Vegyészeti Gyár Rt. | Transzdermális gyógyszerkészítmények |
| US7855195B2 (en) * | 2003-12-02 | 2010-12-21 | Pharmaneuroboost N.V. | Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
| JP2007537232A (ja) * | 2004-05-11 | 2007-12-20 | ファイザー・プロダクツ・インク | 非定型抗精神病薬と５−ｈｔ１ｂ受容体拮抗薬の組合せ |
| WO2005120523A1 (en) * | 2004-06-04 | 2005-12-22 | Mood Management Sciences, Llc | Methods and compositions for treating mood disorder |
| US20060122127A1 (en) * | 2004-11-17 | 2006-06-08 | Cypress Bioscience, Inc. | Methods for reducing the side effects associated with mirtzapine treatment |
| EP1898915A4 (en) * | 2005-07-06 | 2009-01-21 | Sepracor Inc | COMBINATIONS OF ESZOPICLON AND ANTIDEPRESSIVE |
| MX2008007589A (es) * | 2005-12-13 | 2009-01-27 | Trinity Lab Inc | Un metodo para tratar eyaculacion prematura en seres humanos. |
| KR20080097443A (ko) * | 2006-02-03 | 2008-11-05 | 아바니르 파마슈티컬스 | 덱스트로메토판 및 퀴니딘을 포함하는, 우울, 불안 및 신경퇴행성 장애 치료용 약제학적 조성물 |
| US7645750B2 (en) * | 2006-12-13 | 2010-01-12 | Yung Shin Pharmaceutical Ind. Co., Ltd. | Method of treating symptoms of hormonal variations |
| ES2423485T3 (es) * | 2007-03-19 | 2013-09-20 | Acadia Pharmaceuticals Inc. | Asociaciones de agonistas y antagonistas inversos 5-HT2A con antipsicóticos |
| US9216206B2 (en) * | 2008-07-22 | 2015-12-22 | Menogenix, Inc. | Methods of treating symptoms associated with menopause and hormonal variations with G-CSF |
-
2011
- 2011-03-01 PL PL11751180.8T patent/PL2542241T3/pl unknown
- 2011-03-01 JP JP2012556166A patent/JP5839362B2/ja active Active
- 2011-03-01 CN CN201180020427.2A patent/CN102858343B/zh active Active
- 2011-03-01 CA CA2828041A patent/CA2828041C/en active Active
- 2011-03-01 ES ES11751180.8T patent/ES2574210T3/es active Active
- 2011-03-01 EA EA201290851A patent/EA027350B1/ru unknown
- 2011-03-01 AU AU2011223807A patent/AU2011223807B2/en active Active
- 2011-03-01 US US13/037,728 patent/US20110218213A1/en not_active Abandoned
- 2011-03-01 BR BR112012022052-7A patent/BR112012022052B1/pt active IP Right Grant
- 2011-03-01 WO PCT/US2011/026650 patent/WO2011109367A2/en not_active Ceased
- 2011-03-01 EP EP11751180.8A patent/EP2542241B1/en active Active
-
2012
- 2012-08-30 IL IL221706A patent/IL221706A/en active IP Right Grant
-
2016
- 2016-08-10 AU AU2016213776A patent/AU2016213776B2/en active Active
-
2017
- 2017-08-06 IL IL253853A patent/IL253853B/en active IP Right Grant
-
2018
- 2018-07-12 AU AU2018205147A patent/AU2018205147A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013521297A5 (enExample) | ||
| HRP20210343T1 (hr) | Soli ili ko-kristali 3-(3-dimetilamino-1-etil-2-metil-propil)-fenola | |
| FI2442650T4 (fi) | Kielen alle annettava apomorfiini | |
| JP2013520405A5 (enExample) | ||
| JP2009537554A5 (enExample) | ||
| ES2916604T1 (es) | Ensayos de detección de nrf2 y métodos y composiciones relacionados | |
| SG10201407013QA (en) | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases | |
| JP2012255026A5 (enExample) | ||
| AR076864A1 (es) | Procedimiento y composicion para mejorar la absorcion de agentes terapeuticos | |
| JP2011527299A5 (enExample) | ||
| NZ590291A (en) | Pharmaceutical compositions for treatment of parkinson's disease | |
| NZ585219A (en) | Fast release solid formulation, preparation and use thereof | |
| JP2012526854A5 (enExample) | ||
| JP2014218522A5 (enExample) | ||
| RU2012142811A (ru) | Фармацевтические композиции и пероральные дозированные формы пролекарства леводопы и способы применения | |
| HRP20211046T1 (hr) | Upotreba derivata benzimidazola kod noćnog proboja kiseline | |
| JP2009541409A5 (enExample) | ||
| EA201270573A1 (ru) | Гранулированный в расплаве цинакальцет | |
| JP2018039810A5 (enExample) | ||
| RU2018146504A (ru) | Лечение внутрипеченочных холестатических заболеваний | |
| JP2010539130A5 (enExample) | ||
| JP2015512948A5 (enExample) | ||
| GR1008228B (el) | Φαρμακευτικο σκευασμα περιεχον ενα διπλο αναστολεα επαναπροσληψης και μεθοδος για την παρασκευη αυτου | |
| GT201000064A (es) | Formulaciones galénicas de alisquireno | |
| JP2011522850A5 (enExample) |